Loading...

Spark Therapeutics

Nasdaq:ONCE
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ONCE
Nasdaq
$4B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
ONCE Share Price and Events
7 Day Returns
-10.7%
NasdaqGS:ONCE
-0.6%
US Biotechs
0.5%
US Market
1 Year Returns
26%
NasdaqGS:ONCE
-8.8%
US Biotechs
0.8%
US Market
ONCE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Spark Therapeutics (ONCE) -10.7% -9.2% -14.3% 26% 113.5% -
US Biotechs -0.6% -0.9% -9.1% -8.8% 11.6% 4.7%
US Market 0.5% 0.2% 1.1% 0.8% 37.4% 37.5%
1 Year Return vs Industry and Market
  • ONCE outperformed the Biotechs industry which returned -8.8% over the past year.
  • ONCE outperformed the Market in United States of America which returned 0.8% over the past year.
Price Volatility
ONCE
Industry
5yr Volatility vs Market

Value

 Is Spark Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Spark Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Spark Therapeutics.

NasdaqGS:ONCE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:ONCE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.318 (1 + (1- 21%) (2.5%))
1.231
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.23
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.231 * 5.96%)
10.06%

Discounted Cash Flow Calculation for NasdaqGS:ONCE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Spark Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:ONCE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.06%)
2019 -124.33 Analyst x3 -112.96
2020 -162.00 Analyst x2 -133.73
2021 -101.50 Analyst x2 -76.12
2022 -15.00 Analyst x1 -10.22
2023 180.00 Analyst x1 111.44
2024 303.85 Est @ 68.8% 170.91
2025 452.67 Est @ 48.98% 231.34
2026 611.59 Est @ 35.11% 283.98
2027 766.89 Est @ 25.39% 323.53
2028 909.48 Est @ 18.59% 348.60
Present value of next 10 years cash flows $1,136.76
NasdaqGS:ONCE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $909.48 × (1 + 2.73%) ÷ (10.06% – 2.73%)
$12,738.79
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,738.79 ÷ (1 + 10.06%)10
$4,882.70
NasdaqGS:ONCE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,136.76 + $4,882.70
$6,019.46
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $6,019.46 / 38.41
$156.7
NasdaqGS:ONCE Discount to Share Price
Calculation Result
Value per share (USD) From above. $156.70
Current discount Discount to share price of $97.70
= -1 x ($97.70 - $156.70) / $156.70
37.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Spark Therapeutics is available for.
Intrinsic value
38%
Share price is $97.7 vs Future cash flow value of $156.7
Current Discount Checks
For Spark Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Spark Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Spark Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Spark Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Spark Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ONCE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.31
NasdaqGS:ONCE Share Price ** NasdaqGS (2019-06-14) in USD $97.7
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,091 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Spark Therapeutics.

NasdaqGS:ONCE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ONCE Share Price ÷ EPS (both in USD)

= 97.7 ÷ -2.31

-42.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spark Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Spark Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Spark Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGS:ONCE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -42.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
52.7%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.08x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Spark Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Spark Therapeutics's assets?
Raw Data
NasdaqGS:ONCE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $11.76
NasdaqGS:ONCE Share Price * NasdaqGS (2019-06-14) in USD $97.7
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 2.9x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:ONCE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ONCE Share Price ÷ Book Value per Share (both in USD)

= 97.7 ÷ 11.76

8.31x

* Primary Listing of Spark Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spark Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Spark Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Spark Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Spark Therapeutics expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Spark Therapeutics expected to grow at an attractive rate?
  • Spark Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Spark Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Spark Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ONCE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ONCE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 52.7%
NasdaqGS:ONCE Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts 43.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ONCE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ONCE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 614 -49 146 7
2022-12-31 463 -165 -108 7
2021-12-31 293 -162 -95 10
2020-12-31 179 -176 -166 14
2019-12-31 103 -130 -216 12
NasdaqGS:ONCE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 70 -156 -87
2018-12-31 65 -71 -79
2018-09-30 59 -55 -75
2018-06-30 50 -72 -93
2018-03-31 26 -68 -248
2017-12-31 12 -155 -253
2017-09-30 21 -156 -228
2017-06-30 20 -125 -196
2017-03-31 20 -106 -150
2016-12-31 20 -80 -124
2016-09-30 21 -70 -93
2016-06-30 21 -59 -77

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Spark Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Spark Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ONCE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from Spark Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ONCE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.08 28.05 -2.72 7.00
2022-12-31 -2.44 0.41 -5.37 5.00
2021-12-31 -2.20 7.08 -5.25 10.00
2020-12-31 -4.01 -1.01 -6.07 15.00
2019-12-31 -5.57 -5.08 -6.47 9.00
NasdaqGS:ONCE Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.31
2018-12-31 -2.11
2018-09-30 -2.05
2018-06-30 -2.56
2018-03-31 -7.11
2017-12-31 -7.63
2017-09-30 -7.13
2017-06-30 -6.39
2017-03-31 -5.05
2016-12-31 -4.29
2016-09-30 -3.40
2016-06-30 -3.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Spark Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Spark Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Spark Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Spark Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Spark Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Spark Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Spark Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Spark Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Spark Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Spark Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ONCE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 69.82 -86.81 129.40 130.98
2018-12-31 64.73 -78.82 124.60 125.25
2018-09-30 58.98 -75.39 128.88 118.94
2018-06-30 50.17 -93.04 126.22 125.46
2018-03-31 26.47 -247.57 123.20 132.53
2017-12-31 12.07 -253.48 111.12 135.16
2017-09-30 20.96 -228.50 90.95 130.80
2017-06-30 20.36 -196.05 76.36 113.84
2017-03-31 20.17 -150.36 60.31 100.86
2016-12-31 20.18 -123.65 48.07 86.38
2016-09-30 21.08 -92.97 38.47 76.81
2016-06-30 21.08 -77.31 32.88 66.22
2016-03-31 21.08 -62.97 28.54 55.95
2015-12-31 22.06 -47.76 23.35 46.03
2015-09-30 5.48 -51.33 19.18 35.66
2015-06-30 4.18 -41.19 14.83 28.51
2015-03-31 2.89 -31.02 10.53 21.30
2014-12-31 0.63 -25.03 7.86 16.35
2014-09-30 0.02 -80.41 7.36 13.08
2014-06-30 0.02 -75.51 5.78 9.75
2013-12-31 -68.73 2.86 5.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Spark Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Spark Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Spark Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Spark Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Spark Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Spark Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Spark Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Spark Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Spark Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Spark Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 10.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Spark Therapeutics Company Filings, last reported 2 months ago.

NasdaqGS:ONCE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 451.03 93.80 418.78
2018-12-31 496.51 85.41 453.61
2018-09-30 549.88 84.89 590.48
2018-06-30 583.74 35.37 647.23
2018-03-31 479.67 35.75 587.55
2017-12-31 513.62 36.22 520.17
2017-09-30 570.40 1.30 478.70
2017-06-30 228.16 1.38 215.79
2017-03-31 289.55 1.45 253.69
2016-12-31 330.28 1.53 296.17
2016-09-30 359.52 1.58 306.65
2016-06-30 385.63 0.00 332.21
2016-03-31 279.17 0.00 274.97
2015-12-31 290.54 0.00 293.53
2015-09-30 191.70 0.00 212.16
2015-06-30 205.49 0.00 223.05
2015-03-31 216.92 0.00 234.41
2014-12-31 55.21 0.00 74.57
2014-09-30 62.72 0.00 67.27
2014-06-30 68.69 0.00 73.12
2013-12-31 3.37 0.00
  • Spark Therapeutics's level of debt (11.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 11.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Spark Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Spark Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -25.9% each year.
X
Financial health checks
We assess Spark Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Spark Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Spark Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Spark Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Spark Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Spark Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Spark Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ONCE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ONCE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Spark Therapeutics has not reported any payouts.
  • Unable to verify if Spark Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Spark Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Spark Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Spark Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Spark Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Spark Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Spark Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Spark Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Marrazzo
COMPENSATION $3,598,572
AGE 39
TENURE AS CEO 6.4 years
CEO Bio

Mr. Jeffrey D. Marrazzo, also known as Jeff, M.B.A., M.P.A. is a Co-Founder of Spark Therapeutics, Inc. (a/k/a, Spark Therapeutics, LLC) and has been its Chief Executive Officer since 2013. Mr. Marrazzo served as President at Spark Therapeutics, Inc. He is an experienced entrepreneur dedicated to curing disease through genomic medicine. Mr. Marrazzo was part of the founding management of Generation Health, Inc., a pharmacogenomics medicines company that was acquired by CVS Caremark in 2009 and a senior member of the business development and finance teams at Tengion, a venture-backed regenerative medicine company that went public in 2010. He served as Chief Business Officer of Molecular Health AG. He served as Vice President of Sales & Business Development at Generation Health, Inc. Most recently, Mr. Marrazzo launched the U.S. division of Molecular Health, Inc., securing capital and recruiting a management team for this emerging leader in personalized cancer therapy. Throughout his career, he has helped raise or place more than $150 million in venture capital and has led or co-led the formation of novel strategic partnerships with the FDA, Quest Diagnostics, GE Healthcare and SAP. Previously, he served as healthcare advisor to former Pennsylvania Governor Edward G. Rendell and as an IBM management consultant to global pharmaceutical companies. He has also advised investment firms such as Goldman Sachs, Safeguard Scientifics and BioAdvance. He has been a Director of Spark Therapeutics, Inc since 2013. Mr. Marrazzo holds a dual M.B.A./M.P.A. from The Wharton School and Harvard University, a program which he founded and B.A. in Economics and B.S.E. in systems science and Engineering from the University of Pennsylvania.

CEO Compensation
  • Jeff's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jeff's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Spark Therapeutics management team in years:

3.9
Average Tenure
53
Average Age
  • The tenure for the Spark Therapeutics management team is about average.
Management Team

Jeff Marrazzo

TITLE
Co-Founder
COMPENSATION
$4M
AGE
39
TENURE
6.4 yrs

Kathy High

TITLE
Co-Founder
COMPENSATION
$2M
AGE
66
TENURE
4.8 yrs

Stephen Webster

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
57
TENURE
4.9 yrs

Dan Faga

TITLE
Chief Business Officer
COMPENSATION
$3M
AGE
38
TENURE
3.1 yrs

John Furey

TITLE
Consultant
COMPENSATION
$3M
AGE
53
TENURE
0.4 yrs

J. Wright

TITLE
Scientific Co-Founder
AGE
59

Jean Bennett

TITLE
Scientific Co-Founder and Advisor

Bev Davidson

TITLE
Scientific Co-Founder and Advisor

Federico Mingozzi

TITLE
Chief Scientific Officer
AGE
44
TENURE
1.8 yrs

Ryan Asay

TITLE
Head of Investor Relations
Board of Directors Tenure

Average tenure and age of the Spark Therapeutics board of directors in years:

5.1
Average Tenure
58
Average Age
  • The tenure for the Spark Therapeutics board of directors is about average.
Board of Directors

Steven Altschuler

TITLE
Chairman
COMPENSATION
$424K
AGE
65
TENURE
5.7 yrs

Jeff Marrazzo

TITLE
Co-Founder
COMPENSATION
$4M
AGE
39
TENURE
6.1 yrs

Kathy High

TITLE
Co-Founder
COMPENSATION
$2M
AGE
66
TENURE
4.8 yrs

Lars Ekman

TITLE
Director
COMPENSATION
$398K
AGE
68
TENURE
5.1 yrs

Vinnie, Vin Milano

TITLE
Director
COMPENSATION
$388K
AGE
54
TENURE
5 yrs

Lota Zoth

TITLE
Director
COMPENSATION
$399K
AGE
58
TENURE
3.4 yrs

Charles Sigal

TITLE
Director
COMPENSATION
$388K
AGE
66
TENURE
5.4 yrs

Anand Mehra

TITLE
Director
COMPENSATION
$379K
AGE
42
TENURE
5.1 yrs

Rob Perez

TITLE
Director
COMPENSATION
$846K
AGE
54
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
01. Mar 19 Sell The Children's Hospital Of Philadelphia Foundation, Endowment Arm Company 27. Feb 19 27. Feb 19 -2,000,000 $113.00 $-226,000,000
X
Management checks
We assess Spark Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Spark Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does Spark Therapeutics, Inc.'s (NASDAQ:ONCE) CEO Pay Reflect Performance?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Jeff Marrazzo's Compensation Compare With Similar Sized Companies. … is worth US$1.5b, and total annual CEO compensation is US$4.9m.

Simply Wall St -

What You Must Know About Spark Therapeutics Inc's (NASDAQ:ONCE) Financial Health

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Spark Therapeutics Inc (NASDAQ:ONCE), with a market cap of US$2.16b, are often out of the spotlight. … Don’t forget that this is a general and concentrated examination of Spark Therapeutics's financial health, so you should conduct further analysis. … Check out our latest analysis for Spark Therapeutics

Simply Wall St -

Analysts Expect Breakeven For Spark Therapeutics Inc (NASDAQ:ONCE)

The US$2.86b market-cap posted a loss in its most recent financial year of -US$253.48m and a latest trailing-twelve-month loss of -US$247.57m shrinking the gap between loss and breakeven. … I’ve put together a brief outline of industry analyst expectations for ONCE, its year of breakeven and its implied growth rate … View out our latest analysis for Spark Therapeutics

Simply Wall St -

Top Growth Stocks To Buy

Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. … Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. … Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable.

Simply Wall St -

Want To Invest In Spark Therapeutics Inc (NASDAQ:ONCE)? Here's How It Performed Lately

See our latest analysis for Spark Therapeutics Despite a decline, did ONCE underperform the long-term trend and the industry? … For Spark Therapeutics, its most recent earnings (trailing twelve month) is -US$253.48M, which, in comparison to last year’s level, has become more negative. … NasdaqGS:ONCE Income Statement Apr 1st 18 We can further assess Spark Therapeutics's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Has Spark Therapeutics Inc (NASDAQ:ONCE) Got Enough Cash To Cover Its Short-Term Obligations?

See our latest analysis for Spark Therapeutics Does ONCE generate an acceptable amount of cash through operations? … With this growth in debt, the current cash and short-term investment levels stands at $296.2M , ready to deploy into the business. … For Spark Therapeutics, investors should not worry about its debt levels because the company has very, very little on its balance sheet!

Simply Wall St -

An Intrinsic Value Calculation For Spark Therapeutics Inc (NASDAQ:ONCE) Shows Investors Are Overpaying

In this article I am going to calculate the intrinsic value of Spark Therapeutics Inc (NASDAQ:ONCE) by estimating the company's future cash flows and discounting them to their present value. … 5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF ($, Millions) $-167.62 $48.90 $14.90 $74.97 $167.03 Source Analyst x4 Analyst x2 Analyst x2 Analyst x3 Analyst x3 Present Value Discounted @ 10.67% $-151.46 $39.92 $10.99 $49.97 $100.60 Present Value of 5-year Cash Flow (PVCF)= $50 After calculating the present value of future cash flows in the intial 5-year period we need to calculate the Terminal Value, which accounts for all the future cash flows beyond the first stage. … Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = $167 × (1 + 2.5%) ÷ (10.7% – 2.5%) = $2,086 Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = $2,086 / ( 1 + 10.7%)5 = $1,257 The total value, or equity value, is then the sum of the present value of the cash flows, which in this case is $1,307.

Simply Wall St -

With -109.6% Earnings Drop Lately, Did Spark Therapeutics Inc (ONCE) Underperform Its Industry?

Assessing Spark Therapeutics Inc's (NASDAQ:ONCE) past track record of performance is a useful exercise for investors. … Check out our latest analysis for Spark Therapeutics Commentary On ONCE's Past Performance For the purpose of this commentary, I like to use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … You should continue to research Spark Therapeutics to get a better picture of the stock by looking at: 1.

Simply Wall St -

Company Info

Description

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company’s gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company’s preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Details
Name: Spark Therapeutics, Inc.
ONCE
Exchange: NasdaqGS
Founded: 2013
$3,752,975,795
38,413,263
Website: http://www.sparktx.com
Address: Spark Therapeutics, Inc.
3737 Market Street,
Suite 1300,
Philadelphia,
Pennsylvania, 19104,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ONCE Common Stock Nasdaq Global Select US USD 30. Jan 2015
DB 272 Common Stock Deutsche Boerse AG DE EUR 30. Jan 2015
LSE 0L8L Common Stock London Stock Exchange GB USD 30. Jan 2015
Number of employees
Current staff
Staff numbers
368
Spark Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 00:50
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/06/11
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.